Videos

Psychologist Ian Sadler explains why many patients with cancer face anxiety and emotional challenges after treatment ends and why mental health support matters.

Early ASCO data show emiltatug ledadotin produced durable responses in patients with aggressive adenoid cystic carcinoma.

Five-year KEYNOTE-942 data show a personalized cancer vaccine plus Keytruda reduced recurrence risk in patients with high-risk melanoma.

Trodelvy plus Keytruda extended benefit beyond progression in PD-L1-positive metastatic triple-negative breast cancer.

Learn the answers to common questions about bladder cancer, including symptoms, risk factors, stages, BCG therapy, side effects and treatment options.

Dr. Narjust Florez introduces a multidisciplinary panel including nurse practitioner Stephanie McDonald and Megan and Matt Flanagan, a couple navigating ALK-positive non-small cell lung cancer.

Teen cancer survivor Brynn and friend Teddy created Soothe Note, a free app helping patients track symptoms and prepare for appointments.

Dr. John Marshall explains why biomarker testing should be done early in colorectal cancer to guide treatment and identify targeted therapies.

Kassiane Saieed explains how genomic tools provide data to help patients personalize their breast cancer treatment and survivorship.

Dr. Emily Podany links food deserts to aggressive breast cancer mutations and shorter survival, stressing the need for social determinant screening.

Dr. Paolo Tarantino discusses the importance of strategic sequencing and drug-specific prophylaxis to optimize ADC therapy in breast cancer.

KEYNOTE-522 trial data shows adding Keytruda to chemotherapy drastically improves long-term survival for high-risk, early-stage TNBC.

Hear a stage IV melanoma survivor and nurse share TIL therapy insights, healthy-living tips, and why specialized cancer centers matter.

Learn what to expect after TIL therapy: caregiver help, nearby lodging, fatigue recovery, frequent labs, and 24/7 team support for safe healing.

A patient shares motivation after CAR T/TIL therapy as experts reveal caregiver tips for recovery, safety, and avoiding burnout.

First-in-human pancreatic cancer trial at WVU tests an implant that delivers chemotherapy directly into tumors using low-voltage electric pulses.

A cancer survivor’s wife created a life transition binder during his treatment to organize medical, financial and household information to access details in emergencies.

Dr. Maurie Markman, joins The Moonlight Shift to discuss precision medicine's real-world limits, oncology's cost crisis, CAR-T in solid tumors, and the decision support gap costing patients.

Dr. Alexis LeVee and a resilient survivor explore the vital role of self-advocacy in breast cancer care across ages and medical guidelines.

After losing his mother to colorectal cancer, Colorectal Cancer Alliance CEO Michael Sapienza turned grief into advocacy to improve screening, treatment and patient care.

Learn how melanoma patients choose treatment by trusting a care team, preserving identity, and leaning on support to shape personal goals.

After Diane Montalto’s stage 4 colon cancer diagnosis, she and daughter Alyssa turned fear, family support and survival into hope for others.

Patient reveals what keeps him motivated; clinicians explain how caregivers advocate, monitor symptoms, manage meds, and prevent burnout.

Learn how care teams track fluids, vitals and labs during IL-2, manage rigors, hypotension and infection risks in TIL therapy.

Colonoscopies can do more than detect colorectal cancer early — they can prevent it by removing precancerous polyps before cancer develops.

Survivor Erica Deligne discusses "going flat," the power of internal beauty and how fashion helps patients reclaim their autonomy.

Breast cancer survivor Erica Deligne advocates for body autonomy and challenges the medical industry’s default toward breast reconstruction.

The FDA approved Enhertu for presurgical HER2+ breast cancer treatment. Dr. Shanu Modi discusses the "win-win" for patient efficacy and safety.

Learn how non-inferior subcutaneous cancer therapy matches IV efficacy while saving time, easing discomfort, and empowering patient choice.

When treatments work equally well, clinicians weigh patient preferences against logistics to improve cancer care efficiency and experience.